WAKEFIELD, MA, May 7 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and inflammation, today announced the appointment of David B. Holtz as Vice President and Chief Financial Officer, effective May 8, 2008. In these roles, Mr. Holtz will be responsible for oversight of the Controller's Group, Treasury, Risk Management and Information Technology reporting to Thomas E. Gardner, Chairman and Chief Executive Officer of NUCRYST.
"In David Holtz, we are adding a valuable asset to the senior management team at NUCRYST," said Thomas E. Gardner, Chairman and Chief Executive Officer. "David has a proven track record for helping the organizations he has worked for to generate superior value by supporting the successful execution of their business strategies. The breadth and depth of his experience in finance, accounting, compliance, cost control and business development will be of noteworthy value at this time."
Before joining NUCRYST, Mr. Holtz served as financial management consultant for various start-up companies, including Virium Pharmaceuticals, Inc. Previously he worked in various managerial roles of increasing importance at Integra LifeSciences Holdings Corporation from October 1993 through December 2006, most recently as Senior Vice President Finance. While at Integra, Mr. Holtz oversaw Integra's European operations to support the transition of acquisitions in Europe and managed all worldwide financial reporting and accounting functions. Prior to Integra, he worked for Coopers & Lybrand LLP and Cono Leasing Corporation. Mr. Holtz received a B.S. in Business Administration with an emphasis on finance from Susquehanna University and is a Certified Public Accountant.
"I am excited by the opportunity to work with Tom and the NUCRYST
management team," said Mr. Holtz. "I look forward to building long-term
value for NUCRYST shareholders by providing sound, disciplined financia
'/>"/>
| SOURCE NUCRYST Pharmaceuticals Corp. Copyright©2008 PR Newswire. All rights reserved |